Michael Blum
Plus aucun poste en cours
Fortune : 14 770 $ au 30/04/2024
Historique de carrière de Michael Blum
Anciens postes connus de Michael Blum
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| LARIMAR THERAPEUTICS, INC. | Corporate Officer/Principal | 01/04/2015 | 01/11/2017 |
| SAREPTA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/10/2013 | 01/04/2015 |
| Q32 BIO INC. | Corporate Officer/Principal | 01/11/2017 | - |
Formation de Michael Blum
| College of the Holy Cross (Massachusetts) | Undergraduate Degree |
| Babson College | Masters Business Admin |
Statistiques
Internationale
| Etats-Unis | 6 |
Opérationnelle
| Corporate Officer/Principal | 3 |
| Undergraduate Degree | 1 |
| Masters Business Admin | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Homology Medicines, Inc.
 Homology Medicines, Inc. Pharmaceuticals: MajorHealth Technology Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company was founded in March 2015 and is headquartered in Bedford, MA. | Health Technology |
Zafgen, Inc.
 Zafgen, Inc. BiotechnologyHealth Technology Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA. | Health Technology |
- Bourse
- Insiders
- Michael Blum
- Expérience
